Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-25-110444
Filing Date
2025-11-12
Accepted
2025-11-12 16:34:08
Documents
65
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20250930x10q.htm   iXBRL 10-Q 1278098
2 EX-10.5 tmb-20250930xex10d5.htm EX-10.5 43572
3 EX-31.1 tmb-20250930xex31d1.htm EX-31.1 12245
4 EX-31.2 tmb-20250930xex31d2.htm EX-31.2 13303
5 EX-32.1 tmb-20250930xex32d1.htm EX-32.1 6862
6 EX-32.2 tmb-20250930xex32d2.htm EX-32.2 5742
  Complete submission text file 0001104659-25-110444.txt   5947612

Data Files

Seq Description Document Type Size
7 EX-101.SCH tmb-20250930.xsd EX-101.SCH 45277
8 EX-101.CAL tmb-20250930_cal.xml EX-101.CAL 56884
9 EX-101.DEF tmb-20250930_def.xml EX-101.DEF 94406
10 EX-101.LAB tmb-20250930_lab.xml EX-101.LAB 421152
11 EX-101.PRE tmb-20250930_pre.xml EX-101.PRE 273949
68 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20250930x10q_htm.xml XML 973813
Mailing Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104
Business Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104 2674916422
Carisma Therapeutics Inc. (Filer) CIK: 0001485003 (see all company filings)

EIN.: 262025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36296 | Film No.: 251473531
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)